Inactive Instrument

News Lannett Company, Inc.

Stocks

LCI

US5160122009

Pharmaceuticals

All News

Jul. 10	Lannett Company Recalls Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate Extended-Release Capsules Due To Label Mix-Up	CI
Jun. 28	Aurobindo Pharma USA, Inc. completed the acquisition of Lannett Company, Inc.	CI
Jun. 24	Aurobindo Pharma Limited and Lannett Company Inc Federal Trade Commission Proposes Settlement Requiring Divestiture of Generic Drug Products	CI
May. 29	Lannett Company, Inc Recalls Primidone Tablets USP 250mg Due To Cross Contamination	CI
May. 19	FDA Approves Lannett, Lanexa Biologics, And Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar	AQ
25-07-29	Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million.	CI
23-06-16	Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	CI
23-06-16	Lannett Company, Inc. Emerged from Bankruptcy	CI
23-06-08	First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.	CI
23-06-05	First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.	CI
23-05-15	Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-05-04	Motion for Joint Administration Approved for Lannett Company, Inc.	CI
23-05-04	Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.	CI
23-05-03	Motion for Joint Administration Filed by Lannett Company, Inc.	CI
23-05-02	LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION	PR
23-05-02	Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.	CI
23-05-02	Lannett Company, Inc. Filed for Bankruptcy	CI
23-05-01	Lannett Company, Inc. Enters Into Restructuring Support Agreement	PR
23-04-25	Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index	CI
23-04-20	NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS	PR
23-04-14	LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
23-04-14	John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	CI
23-04-14	John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	CI
23-04-04	LANNETT CO INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-04-04	Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	CI